Insulin Prices – Who is the Villain?

 

The standard talking point of many politicians is that pharmaceutical companies are greedy and government should control prices to keep drugs affordable. What is the truth?

Pharmaceutical companies make a lot of money – but they also spend a lot of money to develop their drugs. According to the business services consultancy Deloitte, the average cost of developing a new drug among the top 20 global biopharmaceutical companies rose 15% ($298 million) last year to approximately $2.3 billion. Worse for drug developers, the return on investment reaped by these companies for new drugs and vaccines plunged last year by 82% to 1.2% – the lowest percentage recorded in the 13 years Deloitte launched its annual reports on biopharmaceutical companies R&D – from 6.8% in 2021 and 10.1% in 2010, the first year studied by Deloitte. What other industry would tolerate a 1.2% ROI on a $2.3 Billion investment?

You won’t hear that part of the story in the news because these facts get in the way of the narrative of politicians that the high cost of drugs is due to corporate greed.

Senator Bernie Sanders (D-VT) held a hearing on insulin prices recently and it was contentious, as expected. But Grace-Marie Turner, writing for Galen.org, says it was also surprisingly informative and polite. Top executives of pharmaceutical companies sparred with executives of pharmacy benefit managers (PBMs), pointing fingers over who is responsible for high insulin prices that consumers encounter at the pharmacy. But the debate did illuminate the incredibly complex system of drug pricing.

Eli Lilly Chairman and CEO David Ricks explained that “Lilly hasn’t raised the list price for any of our insulins since 2017, the year I became CEO. In fact, we’ve only cut them.” Their new biosimilar, Humalog, is now available for $25 per vial. Sanofi CEO Paul Hudson said the average net price of Sanofi’s top insulin drug is lower today than it was in 2004 and that his company “returned 84% of our gross insulin sales to payors as rebates.”

The drug companies also are frustrated that the lower-priced version of their drugs seldom make it to PBM formularies. Senators questioned whether the PBMs prefer the higher prices because they get a percentage cut. PBM executives replied they always prioritize the drugs with the lowest price in their complex negotiations with health plans, labor unions, and insurers and pass 98% of rebates along to the customers. PBMs also are revising their formulary schedules to further reduce at-the -counter prices to patients “with an average member out-of-pocket cost below $9 for a 30-day supply of medication,” according to David Joyner, EVP of CVS Health and President, CVS Caremark.

“Today, more than 90% of the prescriptions dispensed are generics and represent a little more than 18% of total spend. And by using competition, generic prices have been deflationary over the last decade,” he said. “Securing affordability for the final 10% of name brand drugs is our focus.” 

Democrats always want to blame the drug companies for high drug prices and always want to solve the problem by government intervention. But Senator Roger Marshall (R-KS) talked about the risks that more government intervention could impede innovation into better products – innovations that continue to extend the life expectancy of diabetics.

Some historical perspective is needed: The first insulins had to be injected multiple times during the day and night, with needles that had to be sharpened, boiled, and reused repeatedly. Today, injections are typically done once a day with throw-away needles that are pre-sterilized and affordable. Blood glucose levels that previously required blood drawing are now available without needle pricks. “The fact is that competition has produced better and better insulin products over time, and we are now seeing prices come down too,” according to Theo Merkel of the Paragon Health Institute in an article for National Review. “Congress should try to address narrow affordability problems where they exist but refrain from soundbite solutions that undermine competition in the long term.”

Unfortunately, the Senate Health, Education, Labor, and Pensions (HELP) Committee couldn’t resist marking up several bills designed to boost competition for generic drugs and increase transparency around PBMs and the insurers that use them. Sen. Rand Paul (R-KY) argued that the committee’s bills are likely to backfire and result in even higher prices.

Just as the Biden Administration repealed all Trump era policies that were effectively limiting illegal border crossings from Mexico, they also repealed a Trump administration solution that addressed the examples Senator Sanders and others raised about patients with lower incomes and no insurance suffering and even dying because they can’t afford their insulin. “A little-noticed policy that would have more directly helped the narrow population that is uninsured or still pays over $35 per prescription was repealed by the Biden administration with little fanfare,” Merkel writes.

He goes on to say, “The Trump administration finalized a rule requiring the nearly 1,400 federally qualified community health centers (FQHCs), which are clinics funded by the federal government to provide community care, to make available insulin at the heavily discounted price they receive under the 340B program (often under $15 per vial) to anyone under 350 percent of the poverty line (roughly $51,000 for a single person).” The option was shut down.

Turner writes, “Despite a sophisticated airing during the hearing of the complex pricing structures and generous patient assistance programs the drug companies offer that even give drugs away to those in need, Sanders concluded by saying ‘There is an enormous amount of greed in the system.”

Never let the facts get in the way of a good political narrative.

Curing Alzheimer’s Too Expensive

The government has decided curing Alzheimer’s Disease isn’t worth the expense. That’s the inevitable conclusion one must reach when weighing the evidence.

I’ve written on this subject before. In a post called Biden Opposing Alzheimer’s Progress, I discussed the report by The Wall Street Journal editorial board that the Centers for Medicare and Medicaid Services (CMS) took the unprecedented step last year of limiting coverage of novel Alzheimer’s drugs. Normally, if the Food and Drug Administration (FDA) approves a drug, Medicare pays for it. But CMS said it wasn’t convinced that a new class of Alzheimer’s drugs is “reasonable and necessary” for seniors.

In that post, I mentioned two new drugs for Alzheimer’s treatment that have been approved by the FDA, but CMS refuses to pay for – Aduhelm and Leqembi. Both have been shown to remove amyloid plaques from the brain, believed to be the cause of Alzheimer’s Disease.

Neurologists posit that removing amyloid could slow progression. A high-dose of Aduhelm removed 71% of plaque buildup. Patients in one trial who received the highest dose also showed 25% to 28% less decline in memory and problem-solving. A second trial showed unclear benefits in part because patients were on the highest dose for less time. FDA, to its credit, showed regulatory flexibility and approved the drug through its accelerated approval pathway based on amyloid clearance.

But Progressives howled about the price at $56,000 per year. But when the manufacturer, Biogen, lowered the price by half, CMS still refused to allow Medicare patients to receive the drug. Then, in January, a new drug named Leqembi was approved by the FDA that showed even more promise in effective treatment. Once again, CMS refused to cover the drug. In response, 20 Senators, including Democrats Gary Peters and Amy Klobuchar, plus 74 House Members including 38 Democrats have joined the fight. The House Members said in a letter to CMS that “access to disease-modifying therapy for Alzheimer’s disease will be extremely limited, nearly nonexistent,” resulting in “irreversible disease progression” and “added burdens for patient caregivers.” But CMS was still unmoved, even though evaluating the safety and efficacy of new drugs is not their role – that’s the role of the FDA.

Joe Grogan, writing for The Wall Street Journal, tells us now we have a third new promising drug that is experiencing the same CMS pushback. The drug is manufactured by Eli Lilly and is called Donanemab. It represents the strongest showing against Alzheimer’s to date. Yet CMS is denying seniors and their families access to these new treatments, and rebuffing innovators who have produced the biggest breakthroughs in Alzheimer’s in two decades.

This issue has bipartisan support – Alzheimer’s Disease is no respecter of political ideology. Democratic and Republican lawmakers hammered CMS Administrator Chiquita Brooks-LaSure on the policy before the House Energy and Commerce Committee’s Subcommittee on Health last week. The same day, 26 attorneys general from red and blue states sent Ms. Brooks-LaSure and Health and Human Services Secretary Xavier Becerra a letter urging them to expand access. Both groups highlighted the administration’s conflicting policy on the matter, noting that the Department of Veterans Affairs granted coverage for Eisai and Biogen’s treatment in February.

The authors say, “In many ways, we are today with Alzheimer’s where we were with cancer 40 years ago. When President Richard Nixon signed the National Cancer Act of 1971, the five-year survival rate was below 50%. After decades of investment, supported by policies rewarding incremental innovation, the rate is approaching 70%. It is nearly 100% for breast, prostate and other cancers caught in the early stages. Similar progress is possible for Alzheimer’s—and the first step is getting FDA-approved treatments out of CED.”

This is not surprising to those who understand the mindset of socialized medicine advocates like the Biden Administration. In all socialized medicine systems, rationing of healthcare according to the value of the individual to society is a mainstay of policy. One can only conclude that seniors are not deemed important enough to justify the expense in this administration.

WHO Declares Covid Pandemic Over

I’m sure you’ll be glad to know the World Health Organization (WHO) has declared the end to the Covid-19 emergency, signaling that one of the deadliest and economically devastating pandemics in modern history is over. By the reactions of most people to wearing masks, personal distancing, and travel in crowded buses and airplanes, this is not really news.

The WHO lost much of its credibility a long time ago at the beginning of this pandemic when they first reassured us there was nothing to worry about, then changed their minds when it was obvious we were experiencing a pandemic. They also aligned themselves with the notoriously untrustworthy Chinese government to reassure us the virus didn’t come from a lab leak in Wuhan. That theory has been widely debunked by now.

This WHO declaration doesn’t really change much, but it does mark a long-awaited milestone, signaling the pandemic is reaching a new stage after more than three years of tragedy and deprivation. Betsy McKay and Brianna Abbott, writing in The Wall Street Journal, tell us more than 6.9 million people have died globally, according to the WHO. In the U.S. alone, the death toll is more than 1.1 million, according to the Centers for Disease Control and Prevention (CDC), and many others have lingering health problems after infection.

Although these numbers have been highly criticized due to the fact that hospitals routinely report Covid deaths in patients who died of other causes, but tested positive for Covid, that’s still a lot of deaths. Covid-19 was the fourth-leading cause of death in the U.S. in 2022 behind heart disease, Cancer, and unintentional injuries including overdoses, according to the CDC. It was the third leading cause of death in 2020 and 2021.

The authors say, “The pandemic has shattered an illusion that humanity has control over its environment. It has wrought significant, often wrenching changes in science, politics and international relations, as well as lessons for global public-health systems. Researchers and public-health officials established global disease surveillance capabilities during the past three years that can be used for future disease monitoring, including wastewater surveillance and genome sequencing.”

That’s the good news. But the bad news is the public has lost trust in public-health officials who promised results with masks, lockdowns of businesses and schools, and vaccines that would prevent illness. When all these promises proved false, the credibility of these officials plummeted. Governments and medical providers are less equipped in many ways to fight disease threats than they were before the pandemic. The next pandemic could be worse.

“The public’s trust in data and in science and vaccines has taken a hit, and it’s been very polarized,” said Dr. Jennifer Kates, a senior vice president at the Kaiser Family Foundation. “It raises the risk of what happens when there’s another pandemic.”

While the pandemic may be over, Covid continues to make its mark. More than 17,000 deaths were reported globally in the past month, according to the WHO. There were about 1,050 reported in the U.S. in the week ending in April 26th. Most of those who are dying are elderly or have conditions that weaken their immune systems.

The U.S. ended its Covid-19 national emergency in April and its public-health emergency will be lifted May 11. That means full insurance coverage for Covid-19 tests won’t be mandatory in many cases and the CDC won’t have the power to collect some test and vaccination data. It also means those who have been kept on Medicaid despite being financially ineligible will lose their coverage. People can get free vaccines and treatments until the government stockpile runs out.